Olanzapine is an atypical antipsychotic that has a pharmacological profile similar that of clozapine. It is biotransformed by hepatic enzymes and can be dosed on a once-daily basis. In large, double-blind, placebo-controlled trials, olanzapine was shown to be efficacious in the treatment of schizophrenia relative to placebo. Many trials showed superior efficacy to haloperidol, especially against negative symptoms. Olanzapine is FDA-approved for the treatment of psychotic disorders, though data suggest possible use in depression, bipolar disorder, psychogenic polydipsia, and developmental disabilities. Olanzap-ine appears to be well-tolerated. Commonly reported adverse effects include orthostatic hypotension, sedation, hepatic transaminase elevations, weight gain, headache, agitation, dizziness, and constipation. The incidence of extrapyramidal symptoms and tardive dyskinesia is low. Few drug interactions have been reported. The recommended starting dose is 10 mg once daily. One trial indicated that the higher cost of this agent might be offset by a reduction in overall hospitalization costs.
KaneJ.M.S.Schizophrenia. N Engl J Med.1996; 334: 34–41.
2.
KaneJ.The current status of neuroleptics. J Clin Psychiatry.1989; 50: 322–8.
3.
HegartyJ.D., BaldessariniR.J., TohenM.One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry.1994; 151: 1409–16.
4.
BreierA., SchreiberJ.L., DyerJ.National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Arch Gen Psychiatry.1991; 48: 329–46.
5.
CorriganP.W., LibermanR.P., EngelJ.D.From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry.1990; 41: 1203–11.
6.
WeidenP.J., ShawE., MannJ.J.Causes of neuroleptic noncompliance. Psychiatric Ann.1986; 16: 571–5.
7.
MilesC.P.Conditions predisposing to suicide: A review. J Nerv Ment Dis.1977; 164: 231–46.
8.
GerlachJ., PeacockL.New antipsy-chotics: The present status. Int Clin Psy-chopharmacol.1995; 10(suppl 3): 39–48.
BeasleyC.M., TollefsonG., TranP.Olanzapine versus placebo and haloperi-dol: Acute phase results of the North American double-blind olanzapine trial. Neurospsychopharmacol.1996; 14: 111–23.
11.
CreeseI., BurtD.R., SnyderS.H.Dopamine receptor binding predicts clinical and pharmacologic potencies of antis-chizophrenic drugs. Science.1976; 192: 481–3.
12.
BymasterF.P., RasmussenK., CalligaroD.O.In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsy-chotic drug. J Clin Psychiatry.1997; 58(suppl 10): 28–36.
13.
MeltzerH.Y., NashJ.F.VII Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev.1991; 43: 587–604.
14.
BymasterF.P., CalligaroD.O., FalconJ.F.Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neu-ropsychopharmacol.1996; 14: 87–96.
15.
KinonB.J., LiebermanJ.A.Mechanisms of action of atypical antipsychotic drugs: A critical analysis. Psychopharmacol.1996; 124: 2–34.
16.
StocktonM.E., RasmussenK.Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of mid-brain dopamine cells. Psychopharmacol (Berl).1996; 124: 50–6.
17.
StocktonM.E., RasmussenK.Electro-physiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacol.1996; 14: 97–104.
18.
ChiodoL.A., BunneyB.S.Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci.1983; 3: 1607–19.
TollefsonG.D., BeasleyC.M., TamuraR.N.Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry.1997; 154: 1248–54.
21.
Zyprexa package insert.Indianapolis, IN: Eli Lilly and Company; March 1997.
22.
RingB.J., CatlowJ., LindsayT.J.Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther.1996; 276: 658–66.
23.
Data on file, Lilly Research Laboratories.
24.
KassahunK., MattiuzE.L., GillespieT.A.Disposition and biotransformation of [14C] olanzapine, a new antipsychotic agent, in humans (Abstract). ISSX Proc.1994; 6: 100.
25.
PerryP.J., SangerT., BeasleyC.Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol.1997; 17: 472–7.
26.
GuyW.ECDEU assessment manual for psychopharmacology, revised version.Bethesda, MD: US Department of Health, Education and Welfare; 1976.
27.
BeasleyC.M., SangerT., SatterleeW.Olanzapine versus placebo: Results of a double-blind, fixeddose olanzapine trial. Psychopharmacol.1996; 124: 159–67.
28.
American Psychiatric Association.DSM-IIIR: Diagnostic and Statistical Manual of Mental Disorders.3rd ed., rev. Washington, DC: American Psychiatric Association Press; 1987.
AndreasenN.C.Negative symptoms in schizophrenia. Arch Gen Psychiatry.1982; 39: 784–8.
33.
BeasleyC.M., HamiltonS.H., CrawfordA.M.Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur Neu-ropsychopharmacol.1997; 7: 125–37.
34.
TollefsonG.D., BeasleyC.M., TranP.V.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry.1997; 154: 457–65.
35.
MontgomeryS.A., ÅsbergM.A new depression scale designed to be sensitive to change. Br J Psychiatry.1979; 134: 382–9.
36.
TranP.V., HamiltonS.H., KuntzA.J.Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol.1997; 17: 407–18.
37.
HeinrichsD.W., HanlonT.E., CarpenterW.T.The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull.1984; 10: 388–98.
38.
ChouinardG., JonesB., RemingtonG.A Canadian multicenter placebo-controlled study of fixed-doses of risperi-done and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol.1993; 13: 25–40.
39.
TollefsonG.D., SangerT.M.Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry.1997; 154: 466–74.
GlazerW.M.Olanzapine and the new generation of antipsychotic agents: Patterns of use. J Clin Psychiatry.1997; 58(suppl 10): 18–21.
42.
DassaD., KaladjianA., AzorinJ.M.Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry.1993; 163: 822–4.
43.
HillertA., MaierW., WetzelH.Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome. Pharmacopsychiatry.1992; 25: 213–7.
44.
DeBattistaC., SolvasonH.B., BelanoffJ.Treatment of psychotic depression [letter]. Am J Psychiatry.1997; 154: 1625–6.
45.
Nemrick-LueckeS.K., SnoddyH.D., FullerR.W.Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci.1994; 55: 479–83.
46.
ZarateC.A., NarendranR., TohenM.Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry.1998; 59: 24–8.
KaneJ.M., HonigfeldG., SingerJ.Clozapine for the treatment-refractory schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry.1988; 45: 789–96.
51.
AlvirJ.M., LiebermanJ.A., SaffermanA.Z.Clozapine-induced agranulocytosis. N Engl J Med.1993; 329: 162–7.
52.
SmithR.C., ChuaJ.W., LipetskerB.Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: An open prospective study. J Clin Psychiatry.1996; 57: 460–6.
53.
MartínJ., GómezJ.C., García-BernardoE.Olanzapine in treatment-refractory schizophrenia: results of an open-label study. J Clin Psychiatry.1997; 58: 479–83.
54.
SheitmanB.B., LindgrenJ.C., EarlyJ., SvedM.High-dose olanzapine for treatment-refractory schizophrenia [letter]. Am J Psychiatry.1997; 154: 1626.
55.
FriedmanJ.H.The management of levodopa psychoses. Clin Neuropharma-col.1991; 14: 283–95.
56.
WoltersE.C., JansenE.N.H., Tuynman-QuaH.G.Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology.1996; 47: 1085–7.
57.
LittrellK.H., JohnsonC.G., LittrellS.H.Effects of olanzapine on polydipsia and intermittent hyponatremia [letter]. J Clin Psychiatry.1997; 58: 549.
58.
LeadbetterR.A., ShuttyM.S.JrDifferential effects of neuroleptics and clozapine on polydipsia and intermittent hypona-tremia. J Clin Psychiatry.1994; 55(9, suppl B): 110–3.
59.
HorriganJ.P., BarnhillL.J., CourvoisieH.E.Olanzapine in PDD [letter]. J Am Acad Child Adolesc Psychiatry.1997; 36: 1166–7.
60.
SaltzB.L., WoernerM.G., KaneJ.M.Prospective study of tardive dyskinesia incidence in the elderly. JAMA.1991; 266: 2402–6.
61.
GelenbergA.J.Psychoses. In: BassukE.L., SchoonoverS.C., GelenbergA.J., eds. The Practitioner's Guide to Psychoactive Drugs.2nd ed.New York, NY: Plenum Medical Book Company; 1983, 115–65.
62.
CrawfordA.M.K., BeasleyC.M., TollefsonG.D.The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res.1997; 26: 41–54.
63.
GoffD.C., ShaderR.I.Non-neurological side effects of antipsychotic agents. In: HirschS.R., WeinbergerD.R., eds. Schizophrenia.Oxford, England: Blackwell Science; 1995, 566–86.
64.
MeltzerH.Y.Atypical antipsychotic drugs. In: BloomF.E., KupperD.J., eds. Psychopharmacology: The Fourth Generation of Progress.New York, NY: Raven Press; 1995, 1277–86.
BakerR.W., ChengappaK.N.R., BairdJ.W.Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry.1992; 53: 439–42.
69.
RemingtonG., AdamsM.Risperidone and obsessive-compulsive symptoms. J Clin Psychopharmacol.1994; 14: 358–9.
70.
BakerR.W., AmesD., UmbrichtD.S.G., ChengappaK.N.R.Obsessive-compulsive symptoms in schizophrenia: A comparison of olanzapine and placebo. Psychopharmacol Bull.1996; 32: 89–93.
71.
FultonB., GoaK.L.Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs.1997; 53: 281–98.
72.
ReusV.I.Olanzapine: A novel atypical neuroleptic agent. Lancet.1997; 349: 1264–5.
73.
BartholiniG.Interactions of striatal dopaminergic, cholinergic, and GABA-ergic neurons: Relation to extrapyramidal function. Trends Pharmacol Sci.1980; 1: 138–40.
74.
TranP.V., DellvaM.A., TollefsonG.D.Extrapyramidal symptoms and tolera-bility of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry.1997; 58: 205–11.
75.
KurzthalerI., HummerM., KohlC.Propranolol treatment of olanzapine-induced akathisia [letter]. Am J Psychiatry.1997; 154: 1316.
76.
KaneJ.M., WoernerM., WeinholdP.Incidence of tardive dyskinesia: Five year data from a prospective study. Psy-chopharmacol Bull.1984; 20: 39–40.
SmithJ.M., BaldessariniR.J.Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry.1980; 37: 1368–73.
80.
KaneJ.M., WoernerM., BorensteinM.Integrating incidence and prevalence of tardive dyskinesia. Psychophar-macol Bull.1986; 22: 254–8.
81.
FentonW.S., WyattR.J., McGlashanT.H.Risk factors for spontaneous dyskine-sia in schizophrenia. Arch Gen Psychiatry.1994; 51: 643–50.
82.
BaileyL., MaxwellS., BrandaburM.M.Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull.1997; 33: 177–81.
83.
WoernerM.G., SaltzB.L., KaneJ.M.Diabetes and development of tardive dyskinesia. Am J Psychiatry.1993; 150: 966–8.
84.
WoernerM.G., SheitmanB.B., Lieber-manJ.A.Tardive dyskinesia induced by risperidone?[letter] Am J Psychiatry.1996; 153: 843.
85.
LiebermanJ.A., SaltzB.L., JohnsC.A.The effects of clozapine on tardive dyskinesia. Br J Psychiatry.1991; 158: 503–10.
86.
SchoolerN.R., KaneJ.M.Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry.1982; 39: 486–7.
87.
GlazerW.M., MorgensternH., DoucetteJ.T.Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J Clin Psychiatry.1993; 54: 133–9.
88.
CaseyD.E.Spontaneous and tardive dyskinesia: Clinical and laboratory studies. J Clin Psychiatry.1985; 46: 42–7.
89.
RiceD.P., MillerL.S.The economic burden of schizophrenia: Conceptual and methodological issues, and cost estimates. In: MoscarelliM., RuppA., Sarto-riusN., eds. Handbook of Mental Health Economics and Health Policy. Vol. 1. New York, NY: John Wiley & Sons; 1996: 321–34.
90.
TerkelsenK.G., MenikoffA.Measuring the costs of schizophrenia: Implications for the post-institutional era in the US. PharmacoEconomics.1995; 8: 199–222.
91.
GlazerW.M., JohnstoneB.M.Pharma-coeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry.1997; 58(suppl 10): 50–4.
